VolitionRX

214 articles with VolitionRX

• VolitionRX Files Two Patent Applications

  4/4/2013

• VolitionRX Hires Head of US Operations, Jason Terrell MD

  3/26/2013

• VolitionRX Announces Collaboration With Wales Cancer Bank

  1/9/2013

• VolitionRX Launches NuQ&#0174 Epigenetic Immunoassays for Research Use

  12/17/2012

• VolitionRX's Preliminary Diagnostic Clinical Trial Results Show High Sensitivity and Specificity for Colon, Breast and Lung Cancers

  11/5/2012

• VolitionRX to Begin Prospective Clinical Trial in Colon Cancer

  8/21/2012

• VolitionRX Issues CEO Letter to Shareholders

  7/16/2012

• VolitionRX Signs Collaboration Agreement With Stefan Holdenrieder of Rheinische Friedrich-Wilhelms-Universitat Bonn Germany

  7/9/2012

• VolitionRX Raises Over $1 Million to Begin Clinical Trials of Blood Based Diagnostic Tests

  5/14/2012

• VolitionRX Release: Pioneering New Science Nucleosomics Advances Blood Based Diagnostics for Cancer

  3/28/2012

• VolitionRX to Test Its Cancer Diagnostics Platform With Abcodia's Biobank

  2/20/2012

• VolitionRX Limited Intellectual Property Update: New Patent Filed

  12/22/2011

• VolitionRX Limited Issues 525,000 Shares to ValiRx Plc; Final Requirement of Share Purchase Agreement

  12/9/2011

• VolitionRX Subsidiary Enters Into its First Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures

  11/15/2011